Cargando…
Clinical Use of Propranolol Reduces Biomarkers of Proliferation in Gastric Cancer
Gastric cancer has one of the highest mortality rate in the world, but the treatment is still limited. Building on previous studies, mechanistic studies on propranolol in gastric cancer mice models and gastric cancer patients were performed. Propranolol inhibited the in vitro proliferation of gastri...
Autores principales: | Hu, Qian, Liao, Ping, Li, Wei, Hu, Jiali, Chen, Cuiyu, Zhang, Yu, Wang, Yang, Chen, Ling, Song, Kun, Liu, Jie, Zhang, Wei, Li, Qing, McLeod, Howard L., He, Yijing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108985/ https://www.ncbi.nlm.nih.gov/pubmed/33981600 http://dx.doi.org/10.3389/fonc.2021.628613 |
Ejemplares similares
-
Propranolol suppresses bladder cancer by manipulating intracellular pH via NHE1
por: Hu, Qian, et al.
Publicado: (2022) -
β-adrenergic receptor inhibition enhances oncolytic herpes virus propagation through STAT3 activation in gastric cancer
por: Hu, Jiali, et al.
Publicado: (2021) -
Transarterial arterial sclerosing embolization for the treatment of propranolol-resistant subglottic hemangioma: Feasibility and effificacy
por: Liu, Zhuang, et al.
Publicado: (2023) -
Topical Timolol Vs. Oral Propranolol for the Treatment of Superficial Infantile Hemangiomas
por: Wu, Hai Wei, et al.
Publicado: (2018) -
Genome-scale analysis identifies SERPINE1 and SPARC as diagnostic and prognostic biomarkers in gastric cancer
por: Liao, Ping, et al.
Publicado: (2018)